Global Osteomalacia Treatment Market, By Type (Nutritional Deficiency, Vitamin-D Hydroxylase Deficiency, Gastrointestinal and Hepatic Disease, Hypoparathyroidism, Pseudohypoparathyroidism, Chronic Renal Insufficiency), Treatment (Supplements of Vitamin D), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Osteomalacia treatment Market Analysis and Size
In the recent times, the market for osteomalacia treatment has gained a major momentum, due to the increasing prevalence of osteomalacia across the world. With the increasing advancements in the drugs to boost their efficiency, this market is likely to report healthy growth during the next few years. Around 40% of the overall U.S. population is seen to be suffering from the deficiency of vitamin D, which is contributing to the high prevalence of bone-related disorders in the country.
Data Bridge Market Research analyses a growth rate in the osteomalacia treatment market in the forecast period 2023-2030. The expected CAGR of osteomalacia treatment market is tend to be around 3% in the mentioned forecast period. The market was valued at USD 114.6 million in 2022, and it would grow upto USD 145.17 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Osteomalacia treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023-2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Nutritional Deficiency, Vitamin-D Hydroxylase Deficiency, Gastrointestinal and Hepatic Disease, Hypoparathyroidism, Pseudohypoparathyroidism, Chronic Renal Insufficiency), Treatment (Supplements of Vitamin D), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Kyowa Kirin International plc. (U.K.), ZERIA Pharmaceutical Co.,Ltd (Japan), Alexion Pharmaceuticals, Inc (U.S.), Pfizer Inc (U.S.), GSK Plc. (U.K.), Sun Pharmaceutical Industries Ltd. (India), Mankind Pharma (India), Pharmavite (U.S.), CHEMVON BIOTECHNOLOGY (SHANGHAI) CO. LTD (China), Abbott (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Osteomalacia is defined as the pronounced softening of the bones, most likely because of the serious deficiency of vitamin D. During development, the weakened bones of children and young adults having osteomalacia can lead to bowing, predominantly in the weight-bearing leg bones. This condition can cause fractures in older adults. Cancer, autoimmune disorders, liver diseases, several drugs, such as phenytoin and phenobarbital, and certain surgeries, such as stomach surgery, are also the reasons that can cause osteomalacia.
Global Osteomalacia treatment Market Dynamics
Drivers
- Rising Prevalence of Bone-Related Disorders
Increasing bone-related disorders is boosting the market. Every year an estimated 1.5 million individuals suffer a fracture because of the bone disease. Approximately 4 in 10 women, age 50 or older in the U.S. will experience a hip, spine, or wrist fracture sometime during the remainder of their lives. An estimated one million individuals in the U.S. have Paget’s disease. Thus, all these factors are boosting the growth of the market
- Increasing Incidence in Elderly Population
Osteomalacia cases are mostly witnessed in the age group ≤ 40 years, 41−60 years, and > 60 years. The >60 years group saw the highest number of patients, mostly around 10,275 in 2021 in the U.S. In 2021, treatment eligible population of osteoporosis accounted for 9,511 cases in the U.S. Thus, this elderly population has higher chances of getting this disease boosts the market growth.
Opportunities
- Wide Availability of Osteomalacia Drugs
The wide availability of novel drugs, such as burosumab and parathyroid hormone (PTH) for the treatment of pediatric and adult patients suffering from hypophosphatemia is also boosting the demand for osteomalacia drugs. The U.S. FDA granted the breakthrough therapy designation to Asfotase Alfa in 2015, that is anticipated to support the global market in the next few years.
- Increasing Collaborations and Market Expansion
An increase in the commencing of joint ventures between major market players with several other factors such as the family history of members diagnosed with osteomalacia disease, long term usage of medicines which affects bone density in the body played an important role in the growth of the market. Thus, these factors are growing the market.
Restraints/Challenges
- Lack of Awareness
The lack of awareness about the diseased condition and the wide unavailability of numerous awareness programs limit the market growth. The available drugs have not shown disease-modifying activity and are still mostly inadequate for managing major unmet needs.
- High Cost
Patent expiry and loss of exclusivity are considered major restraints of the osteomalacia drugs market. The loss of patent exclusivity of a branded drug results in drastic revenue reduction amounting to nearly 35% - 40% in the first year. This low cost of generics results in increasing consumption, although generic drugs cannot achieve or exceed the overall sales of the branded formulation.
This osteomalacia treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the osteomalacia treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Osteomalacia Treatment Market Scope
The osteomalacia treatment market is segmented on the basis of treatment, type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Nutritional Deficiency
- Vitamin-D Hydroxylase Deficiency
- Gastrointestinal and Hepatic Disease
- Hypoparathyroidism
- Pseudohypoparathyroidism
- Chronic Renal Insufficiency
Treatment
- Supplements of Vitamin D
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Osteomalacia Treatment Market Regional Analysis/Insights
The osteomalacia treatment market is analyzed and market size insights and trends are provided by treatment, type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the osteomalacia treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing positive growth for osteomalacia treatment market throughout the forecasted period due to the ongoing growth of medical and healthcare infrastructure in prominent Asian economies and the existence of a wide patient pool in this area.
North America dominates the market due to increased spending by the government in the region for research and development.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Osteomalacia treatment Market Share Analysis
The osteomalacia treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to osteomalacia treatment market.
Key players operating in the osteomalacia treatment market include:
- Kyowa Kirin International plc. (U.K.)
- ZERIA Pharmaceutical Co.,Ltd (Japan).
- Alexion Pharmaceuticals, Inc (U.S.)
- Pfizer Inc (U.S.).
- GSK Plc. (U.K.)
- Sun Pharmaceutical Industries Ltd. (India)
- Mankind Pharma (India)
- Pharmavite (U.S.)
- CHEMVON BIOTECHNOLOGY (SHANGHAI) CO. LTD (China)
- Abbott (U.S.)
SKU-